To Get Full Access :

Login with Linked
Login with Gmail

Follow us on

Link Linkedin Youtube

Imdelltra

Imdelltra is used to treat adults with extensive-stage small cell lung cancer (ES-SCLC) that has returned after platinum-based chemotherapy.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

  • Molecule Name :

    Tarlatamab-Dlle

  • Innovator :

    AMGEN

  • Approval Date :

    16-May-24

  • Data Exclusivity Expiry :

    16-May-28

  • Market Exclusivity Expiry :

    16-May-36

  • Dosage Form :

    Intravenous Infusion

  • Strength :

    1mg/vial and 10mg/vial

  • Therapeutic Category :

    Anticancer

  • Revenue ($M) :

    115

Year-wise Projected Sales ($M) :

  • 2025 :

    536

  • 2026 :

    793

  • 2027 :

    1,044

  • 2028 :

    1,388

  • 2029 :

    1,616

  • 2030 :

    1,688

  • 2031 :

    2,029
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Partner With Us

  • Supported 1000+ clinical trials globally
  • Provides services across regulatory, legal & clinical research
  • Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
  • Integrated CRO services as part of our offerings
  • Insights on global pricing for smarter clinical trial supply decisions
  • Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
Contact Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login With

For full access Sign-up / Sign-in using below Methods:

Linked
Gmail

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?